Sable Therapeutics

Sable Therapeutics is a New York-based biotech company specializing in innovative, non-invasive fat reduction technologies. It focuses on developing effective solutions for weight management and body contouring, catering to both consumers and medical professionals. Founded in 2020 and headquartered in New York, US, Sable Therapeutics develops advanced fat reduction technologies targeting adipose tissue. The company has completed one deal as of September 12, 2025.

The specific details about the founder and any previous ventures are not publicly disclosed. Sable Therapeutics specializes in innovative solutions for fat reduction, with a primary focus on its proprietary fat reduction technology that targets adipose tissue through non-invasive methods. This approach addresses challenges in weight management and aesthetic enhancement, appealing to consumers seeking effective body contouring solutions. The company’s products are designed for individual consumers and medical professionals, enhancing their ability to provide advanced treatment options.

Sable Therapeutics markets its products primarily in North America and Europe, serving wellness clinics, cosmetic surgeons, and end users interested in improving their body composition and overall health. Sable Therapeutics generates revenue through direct-to-consumer sales and partnerships with medical facilities. The company conducts transactions with wellness centers that incorporate its technology into their treatment offerings. Pricing structures are based on service utilization and may include subscription models for ongoing treatments or one-time fees for each session.

The flagship product is central to these transactions, directly correlating the technology's effectiveness with client satisfaction. In September 2025, Sable Therapeutics raised an undisclosed amount of Seed funding from new investor SOSV. The company plans to utilize this funding to support the development of upcoming products and expand into new markets. Specific geographic targets for expansion have not been publicly disclosed, nor have any upcoming product launch dates.

However, the investment will likely facilitate advancements in their existing offerings and support broader market reach.